82_FR_14960 82 FR 14905 - Center for Scientific Review; Notice of Closed Meeting

82 FR 14905 - Center for Scientific Review; Notice of Closed Meeting

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

Federal Register Volume 82, Issue 55 (March 23, 2017)

Page Range14905-14906
FR Document2017-05750

Federal Register, Volume 82 Issue 55 (Thursday, March 23, 2017) 
[Federal Register Volume 82, Number 55 (Thursday, March 23, 2017)]
[Notices]
[Pages 14905-14906]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2017-05750]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Center for Scientific Review; Notice of Closed Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. App.), notice is hereby given of the following 
meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: Center for Scientific Review Special Emphasis 
Panel; Member Conflict: Oncology 1 Basic Translational.
    Date: April 6, 2017.
    Time: 1:00 p.m. to 5:00 p.m.

[[Page 14906]]

    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, 6701 Rockledge Drive, 
Bethesda, MD 20892 (Virtual Meeting).
    Contact Person: Amy L. Rubinstein, Ph.D., Scientific Review 
Officer, Center for Scientific Review, National Institutes of 
Health, 6701 Rockledge Drive, Room 5152, MSC 7844, Bethesda, MD 
20892, 301-408-9754, [email protected].

(Catalogue of Federal Domestic Assistance Program Nos. 93.306, 
Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333, 
93.337, 93.393-93.396, 93.837-93.844, 93.846-93.878, 93.892, 93.893, 
National Institutes of Health, HHS)

    Dated: March 17, 2017.
Michelle Trout,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2017-05750 Filed 3-22-17; 8:45 am]
 BILLING CODE 4140-01-P

Federal Register / Vol. 82, No. 55 / Thursday, March 23, 2017 / Notices 14905 instructions for submitting comments. the claimed confidential information, in practices regulation (21 CFR 10.115). Comments submitted electronically, its consideration of comments. The The draft guidance, when finalized, will including attachments, to http:// second copy, which will have the represent the current thinking of FDA www.regulations.gov will be posted to claimed confidential information on developing drugs for the prevention the docket unchanged. Because your redacted/blacked out, will be available of DGF in kidney transplant. It does not comment will be made public, you are for public viewing and posted on http:// establish any rights for any person and solely responsible for ensuring that your www.regulations.gov. Submit both is not binding on FDA or the public. comment does not include any copies to the Division of Dockets You can use an alternative approach if confidential information that you or a Management. If you do not wish your it satisfies the requirements of the third party may not wish to be posted, name and contact information to be applicable statutes and regulations. such as medical information, your or made publicly available, you can anyone else’s Social Security number, or provide this information on the cover II. The Paperwork Reduction Act of confidential business information, such sheet and not in the body of your 1995 as a manufacturing process. Please note comments and you must identify this This guidance refers to previously that if you include your name, contact information as ‘‘confidential.’’ Any approved collections of information that information, or other information that information marked as ‘‘confidential’’ are subject to review by the Office of identifies you in the body of your will not be disclosed except in Management and Budget (OMB) under comments, that information will be accordance with 21 CFR 10.20 and other the Paperwork Reduction Act of 1995 posted on http://www.regulations.gov. applicable disclosure law. For more (44 U.S.C. 3501–3520). The collections • If you want to submit a comment information about FDA’s posting of of information in 21 CFR parts 312 and with confidential information that you comments to public dockets, see 80 FR 314 have been approved under OMB do not wish to be made available to the 56469, September 18, 2015, or access control numbers 0910–0014 and 0910– public, submit the comment as a the information at: http://www.fda.gov/ 0001, respectively. written/paper submission and in the regulatoryinformation/dockets/ manner detailed (see ‘‘Written/Paper default.htm. III. Electronic Access Submissions’’ and ‘‘Instructions’’). Docket: For access to the docket to Persons with access to the Internet read background documents or the may obtain the draft guidance at either Written/Paper Submissions electronic and written/paper comments http://www.fda.gov/Drugs/ Submit written/paper submissions as received, go to http:// GuidanceCompliance follows: www.regulations.gov and insert the RegulatoryInformation/Guidances/ • Mail/Hand delivery/Courier (for docket number, found in brackets in the default.htm or http:// written/paper submissions): Division of heading of this document, into the www.regulations.gov. Dockets Management (HFA–305), Food ‘‘Search’’ box and follow the prompts Dated: March 20, 2017. and Drug Administration, 5630 Fishers and/or go to the Division of Dockets Lane, Rm. 1061, Rockville, MD 20852. Leslie Kux, Management, 5630 Fishers Lane, Rm. • For written/paper comments 1061, Rockville, MD 20852. Associate Commissioner for Policy. submitted to the Division of Dockets Submit written requests for single [FR Doc. 2017–05818 Filed 3–22–17; 8:45 am] Management, FDA will post your copies of the draft guidance to the BILLING CODE 4164–01–P comment, as well as any attachments, Division of Drug Information, Center for except for information submitted, Drug Evaluation and Research, Food marked and identified, as confidential, and Drug Administration, 10001 New DEPARTMENT OF HEALTH AND if submitted as detailed in Hampshire Ave., Hillandale Building, HUMAN SERVICES ‘‘Instructions.’’ 4th Floor, Silver Spring, MD 20993– Instructions: All submissions received 0002. Send one self-addressed adhesive National Institutes of Health must include the Docket No. FDA– label to assist that office in processing Center for Scientific Review; Notice of 2017–D–0198 for ‘‘Delayed Graft your requests. See the SUPPLEMENTARY Closed Meeting Function in Kidney Transplantation: INFORMATION section for electronic Developing Drugs for Prevention; Draft access to the draft guidance document. Pursuant to section 10(d) of the Guidance for Industry; Availability.’’ FOR FURTHER INFORMATION CONTACT: Federal Advisory Committee Act, as Received comments will be placed in Ozlem Belen, Center for Drug amended (5 U.S.C. App.), notice is the docket and, except for those Evaluation and Research, Food and hereby given of the following meeting. submitted as ‘‘Confidential Drug Administration, 10903 New The meeting will be closed to the Submissions,’’ publicly viewable at Hampshire Ave, Bldg. 22, Rm. 6118, public in accordance with the http://www.regulations.gov or at the Silver Spring, MD 20993–0002, 301– provisions set forth in sections Division of Dockets Management 796–0676. 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., between 9 a.m. and 4 p.m., Monday SUPPLEMENTARY INFORMATION: as amended. The grant applications and through Friday. the discussions could disclose • Confidential Submissions—To I. Background confidential trade secrets or commercial submit a comment with confidential FDA is announcing the availability of property such as patentable material, information that you do not wish to be a draft guidance for industry entitled and personal information concerning made publicly available, submit your ‘‘Delayed Graft Function in Kidney individuals associated with the grant comments only as a written/paper sradovich on DSK3GMQ082PROD with NOTICES Transplantation: Developing Drugs for applications, the disclosure of which submission. You should submit two Prevention.’’ The purpose of this would constitute a clearly unwarranted copies total. One copy will include the guidance is to assist sponsors in the invasion of personal privacy. information you claim to be confidential clinical development of drugs for the Name of Committee: Center for Scientific with a heading or cover note that states prevention of DGF in kidney Review Special Emphasis Panel; Member ‘‘THIS DOCUMENT CONTAINS transplantation. Conflict: Oncology 1 Basic Translational. CONFIDENTIAL INFORMATION.’’ The This draft guidance is being issued Date: April 6, 2017. Agency will review this copy, including consistent with FDA’s good guidance Time: 1:00 p.m. to 5:00 p.m. VerDate Sep<11>2014 17:13 Mar 22, 2017 Jkt 241001 PO 00000 Frm 00041 Fmt 4703 Sfmt 4703 E:\FR\FM\23MRN1.SGM 23MRN1

14906 Federal Register / Vol. 82, No. 55 / Thursday, March 23, 2017 / Notices Agenda: To review and evaluate grant Research; 93.862, Genetics and Health, 6701 Rockledge Drive, Room 5216, applications. Developmental Biology Research; 93.88, MSC 7852, Bethesda, MD 20892, 301–435– Place: National Institutes of Health, 6701 Minority Access to Research Careers; 93.96, 1050, freundr@csr.nih.gov. Rockledge Drive, Bethesda, MD 20892 Special Minority Initiatives; 93.859, This notice is being published less than 15 (Virtual Meeting). Biomedical Research and Research Training, days prior to the meeting due to the timing Contact Person: Amy L. Rubinstein, Ph.D., National Institutes of Health, HHS) limitations imposed by the review and Scientific Review Officer, Center for funding cycle. Scientific Review, National Institutes of Dated: March 15, 2017. Name of Committee: Center for Scientific Health, 6701 Rockledge Drive, Room 5152, Melanie J. Pantoja, Review Special Emphasis Panel; Voice MSC 7844, Bethesda, MD 20892, 301–408– Program Analyst, Office of Federal Advisory Production. 9754, rubinsteinal@csr.nih.gov. Committee Policy. Date: April 11, 2017. (Catalogue of Federal Domestic Assistance [FR Doc. 2017–05587 Filed 3–22–17; 8:45 am] Time: 2:00 p.m. to 3:00 p.m. Program Nos. 93.306, Comparative Medicine; Agenda: To review and evaluate grant BILLING CODE 4140–01–P 93.333, Clinical Research, 93.306, 93.333, applications. 93.337, 93.393–93.396, 93.837–93.844, Place: National Institutes of Health, 6701 93.846–93.878, 93.892, 93.893, National Rockledge Drive, Bethesda, MD 20892 Institutes of Health, HHS) DEPARTMENT OF HEALTH AND (Telephone Conference Call). HUMAN SERVICES Contact Person: Biao Tian, Ph.D., Scientific Dated: March 17, 2017. Review Officer, Center for Scientific Review, Michelle Trout, National Institutes of Health National Institutes of Health, 6701 Rockledge Program Analyst, Office of Federal Advisory Drive, Room 3089B, MSC 7848, Bethesda, Committee Policy. Center for Scientific Review; Notice of MD 20892, (301) 402–4411, tianbi@ [FR Doc. 2017–05750 Filed 3–22–17; 8:45 am] Closed Meetings csr.nih.gov. BILLING CODE 4140–01–P Pursuant to section 10(d) of the Name of Committee: Center for Scientific Federal Advisory Committee Act, as Review Special Emphasis Panel; Member Conflict: Neurodevelopmental Disorders. amended (5 U.S.C. App.), notice is DEPARTMENT OF HEALTH AND Date: April 13, 2017. hereby given of the following meetings. Time: 10:00 a.m. to 12:01 p.m. HUMAN SERVICES The meetings will be closed to the Agenda: To review and evaluate grant public in accordance with the applications. National Institutes of Health provisions set forth in sections Place: National Institutes of Health, 6701 National Institute of General Medical 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., Rockledge Drive, Bethesda, MD 20892 Sciences; Notice of Closed Meeting as amended. The grant applications and (Telephone Conference Call). the discussions could disclose Contact Person: Samuel C. Edwards, Ph.D., Pursuant to section 10(d) of the confidential trade secrets or commercial Chief, Brain Disorders and Clinical Federal Advisory Committee Act, as property such as patentable material, Neuroscience, Center for Scientific Review, amended (5 U.S.C. App.), notice is National Institutes of Health, 6701 Rockledge and personal information concerning hereby given of the following meeting. Drive, Room 5210, MSC 7846, Bethesda, MD individuals associated with the grant 20892, (301) 435–1246, edwardss@ The meeting will be closed to the applications, the disclosure of which csr.nih.gov. public in accordance with the would constitute a clearly unwarranted Name of Committee: Center for Scientific provisions set forth in sections invasion of personal privacy. Review Special Emphasis Panel; Member 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., Conflict: Neuroendocrinology, Sleep, Stress, Name of Committee: Center for Scientific as amended. The grant applications and Review Special Emphasis Panel; Member and Alcohol. the discussions could disclose Conflict: International and Cooperative Date: April 14, 2017. confidential trade secrets or commercial Projects 1. Time: 9:00 a.m. to 6:00 p.m. property such as patentable material, Date: April 6, 2017. Agenda: To review and evaluate grant and personal information concerning Time: 9:00 a.m. to 10:00 a.m. applications. individuals associated with the grant Agenda: To review and evaluate grant Place: National Institutes of Health, 6701 applications, the disclosure of which applications. Rockledge Drive, Bethesda, MD 20892 Place: National Institutes of Health, 6701 (Virtual Meeting). would constitute a clearly unwarranted Rockledge Drive, Bethesda, MD 20892 Contact Person: Nicholas Gaiano, Ph.D., invasion of personal privacy. (Telephone Conference Call). Scientific Review Officer, Center for Name of Committee: National Institute of Contact Person: Brian H. Scott, Ph.D., Scientific Review, National Institutes of General Medical Sciences Special Emphasis Scientific Review Officer, National Institutes Health, 6701 Rockledge Drive, Room 5178, Panel; Loan Repayment Program. of Health, Center for Scientific Review, 6701 MSC 7844, Bethesda, MD 20892–7844, 301– Date: April 18, 2017. Rockledge Drive, Bethesda, MD 20892, 301– 435–1033, gaianonr@csr.nih.gov. Time: 12:00 p.m. to 3:00 p.m. 827–7490, brianscott@mail.nih.gov. Name of Committee: Center for Scientific Agenda: To review and evaluate grant This notice is being published less than 15 Review Special Emphasis Panel; Member applications. days prior to the meeting due to the timing Conflict: Aging Related Discords, Human and Place: National Institutes of Health, limitations imposed by the review and Animal Studies. Natcher Building, Room 3An.12N, 45 Center funding cycle. Date: April 14, 2017. Drive, Bethesda, MD 20892. Name of Committee: Center for Scientific Time: 11:00 a.m. to 1:00 p.m. Contact Person: Manas Chattopadhyay, Review Special Emphasis Panel; Member Agenda: To review and evaluate grant Ph.D., Scientific Review Officer, National Conflict: AIDS and Related Research. applications. Institute of General Medical Sciences, Date: April 7, 2017. Place: National Institutes of Health, 6701 National Institute of Health, Building 45, Time: 1:00 p.m. to 4:00 p.m. Rockledge Drive, Bethesda, MD 20892 sradovich on DSK3GMQ082PROD with NOTICES Room 3An12N, 45 Center Drive, Bethesda, Agenda: To review and evaluate grant (Telephone Conference Call). MD 20892, 301–827–5320, manasc@ applications. Contact Person: Samuel C. Edwards, Ph.D., mail.nih.gov. Place: National Institutes of Health, 6701 Chief, Brain Disorders and Clinical (Catalogue of Federal Domestic Assistance Rockledge Drive, Bethesda, MD 20892 Neuroscience, Center for Scientific Review, Program Nos. 93.375, Minority Biomedical (Telephone Conference Call). National Institutes of Health, 6701 Rockledge Research Support; 93.821, Cell Biology and Contact Person: Robert Freund, Ph.D., Drive, Room 5210, MSC 7846, Bethesda, MD Biophysics Research; 93.859, Pharmacology, Scientific Review Officer, Center for 20892, (301) 435–1246, edwardss@ Physiology, and Biological Chemistry Scientific Review, National Institutes of csr.nih.gov. VerDate Sep<11>2014 17:13 Mar 22, 2017 Jkt 241001 PO 00000 Frm 00042 Fmt 4703 Sfmt 4703 E:\FR\FM\23MRN1.SGM 23MRN1


Document Created: 2017-03-23 02:45:46
Document Modified: 2017-03-23 02:45:46
CategoryRegulatory Information
CollectionFederal Register
sudoc ClassAE 2.7:
GS 4.107:
AE 2.106:
PublisherOffice of the Federal Register, National Archives and Records Administration
SectionNotices
DatesApril 6, 2017.
FR Citation82 FR 14905 
2025 Federal Register | Disclaimer | Privacy Policy
USC | CFR | eCFR